EP.007: JAZZ: Value with an Oncology Catalyst - 5x Risk-Reward Ratio | Pitch The PM

Sriker Nadipuram from Critical Value Asset Management discusses Jazz Pharmaceuticals (JAZZ), a healthcare biotech company with a stable base business in neurology and a promising oncology pipeline. Jazz's key drug, Zywave, treats narcolepsy, while Epidiolex addresses rare seizures. A significant catalyst is Zantidatamab (Zyhera), already approved for biliary tract cancer, with potential in gastric and breast cancers. Nadipuram believes the stock is undervalued due to macro concerns like tariffs and tax uncertainties, despite a strong unlevered free cash flow yield. He sees limited downside due to the base business and significant upside if Zantidatamab succeeds, potentially shifting Jazz into an oncology-focused company.

Outlines

Part 1: Introduction, Strategy, and Macro Risks

Part 2: Core Business and Product Portfolio

Part 3: Valuation, Market Sentiment, and Mispricing

Part 4: Clinical Catalysts and Revenue Modeling

Part 5: Risk Management and Conclusion

Sign in to continue reading, translating and more.

Open full episode in Podwise

EP.007: JAZZ: Value with an Oncology Catalyst - 5x Risk-Reward Ratio

Pitch The PM

Part 1: Introduction, Strategy, and Macro Risks

Introduction to Jazz Pharmaceuticals and Sriker Nadipuram's Investment Approach

Sriker's Background, Critical Value's Investment Strategy, and Macroeconomic Concerns

Risk-Reward Analysis of Jazz Pharmaceuticals: Tariffs vs. Clinical Trial Upside

Part 2: Core Business and Product Portfolio

Jazz Pharmaceuticals' Base Business: Zywave for Narcolepsy and Regulatory Barriers

Epidiolex for Rare Seizures, Oncology Pipeline, and Zyhera's Potential

Part 3: Valuation, Market Sentiment, and Mispricing

Financial Projections and Valuation: Free Cash Flow and Pipeline Value

Market Mispricing and Uncertainty: Tariffs, Drug Pricing, and Generalist Investors

Variant View and Generalist Investor Sentiment: Tax Rates and Drug Pricing Concerns

Part 4: Clinical Catalysts and Revenue Modeling

Jazz's High Free Cash Yield and Clinical Trial Catalysts

De-risking the Clinical Trial: Safety, Efficacy, and FDA Approval

Post-Readout Steps, Market Size, and Revenue Modeling

Part 5: Risk Management and Conclusion

Bear Case, Free Cash Flow, and Hedging Strategies

Management Alignment, Capital Return, and Compelling Risk-Reward

EP.007: JAZZ: Value with an Oncology Catalyst - 5x Risk-Reward Ratio

Pitch The PM

Part 1: Introduction, Strategy, and Macro Risks

00:06Introduction to Jazz Pharmaceuticals and Sriker Nadipuram's Investment Approach

Introduction to Jazz Pharmaceuticals and Sriker Nadipuram's Investment Approach

01:19Sriker's Background, Critical Value's Investment Strategy, and Macroeconomic Concerns

Sriker's Background, Critical Value's Investment Strategy, and Macroeconomic Concerns

07:04Risk-Reward Analysis of Jazz Pharmaceuticals: Tariffs vs. Clinical Trial Upside

Risk-Reward Analysis of Jazz Pharmaceuticals: Tariffs vs. Clinical Trial Upside

Part 2: Core Business and Product Portfolio

10:19Jazz Pharmaceuticals' Base Business: Zywave for Narcolepsy and Regulatory Barriers

Jazz Pharmaceuticals' Base Business: Zywave for Narcolepsy and Regulatory Barriers

15:10Epidiolex for Rare Seizures, Oncology Pipeline, and Zyhera's Potential

Epidiolex for Rare Seizures, Oncology Pipeline, and Zyhera's Potential

Part 3: Valuation, Market Sentiment, and Mispricing

19:39Financial Projections and Valuation: Free Cash Flow and Pipeline Value

Financial Projections and Valuation: Free Cash Flow and Pipeline Value

23:50Market Mispricing and Uncertainty: Tariffs, Drug Pricing, and Generalist Investors

Market Mispricing and Uncertainty: Tariffs, Drug Pricing, and Generalist Investors

28:32Variant View and Generalist Investor Sentiment: Tax Rates and Drug Pricing Concerns

Variant View and Generalist Investor Sentiment: Tax Rates and Drug Pricing Concerns

Part 4: Clinical Catalysts and Revenue Modeling

35:44Jazz's High Free Cash Yield and Clinical Trial Catalysts

Jazz's High Free Cash Yield and Clinical Trial Catalysts

40:10De-risking the Clinical Trial: Safety, Efficacy, and FDA Approval

De-risking the Clinical Trial: Safety, Efficacy, and FDA Approval

45:22Post-Readout Steps, Market Size, and Revenue Modeling

Post-Readout Steps, Market Size, and Revenue Modeling

Part 5: Risk Management and Conclusion

50:52Bear Case, Free Cash Flow, and Hedging Strategies

Bear Case, Free Cash Flow, and Hedging Strategies

55:56Management Alignment, Capital Return, and Compelling Risk-Reward

Management Alignment, Capital Return, and Compelling Risk-Reward